TNFRSF8 and systemic mastocytosis: Despite this, in many SM patients, CD30 was not expressed by all tumor BMMC, the percentage of CD30+ BMMC in the different diagnostic subtypes of SM ranging from 0% in MCL patients to 94% in WDSM cases (p = 0.001), respectively (Table 2).